What is the market's earnings forecast for United Therapeutics next quarter?

Did United Therapeutics beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for United Therapeutics year over year?

What guidance did United Therapeutics's management provide for the next earnings period?

What is United Therapeutics's latest dividend and current dividend yield?

What were the key takeaways from United Therapeutics’s earnings call?

What does United Therapeutics do and what are its main business segments?

What is United Therapeutics's gross profit margin?

- **Record Q3 2025 Results**: $800M revenue (+7% YoY), driven by Tyvaso DPI and Orenitram growth.
- **$4B 2027 Run Rate Target**: Ambitious goal reflecting confidence in IPF and PH-ILD expansion.
- **Innovative Product Launches**: 80-microgram Tyvaso DPI cartridge and RemunityPRO pump enhance patient convenience.
- **Ralinepag Partnership Potential**: Long patent life (2040) and synergistic effects position for strategic deals.
- **TETON 2 IPF Impact**: Unblinded data shows unprecedented benefits, with physician interest in dual PH/IPF treatment.

**【CEO Summary Section】**
- United Therapeutics reported record total revenues of $800 million for Q3 2025, a 7% year-over-year increase, driven by Tyvaso and Orenitram sales.
- CEO Martine Rothblatt highlighted the successful enrollment of three Phase III trials and the unblinded results for pulmonary fibrosis (IPF), which showed unprecedented treatment benefits.
- The company is targeting a $4 billion annual revenue run rate by 2027, with a focus on expanding into IPF and PH-ILD markets.
- Rothblatt emphasized the potential for partnerships with large pharma companies (e.g., Merck, J&J) to leverage ralinepag's long patent life (2040) and its synergistic effects with other therapies.

**【COO Summary Section】**
- Michael Benkowitz reported continued double-digit growth for Tyvaso DPI, with no material impact from competitor YUTREPIA's launch.
- The new Tyvaso DPI 80-microgram cartridge enables 15 breaths in a single dose, offering superior dosing flexibility compared to competitors.
- Launch of 96- and 112-microgram combination kits aims to improve access for high-dose patients.
- Remodulin's new RemunityPRO pump enhances patient convenience and home therapy initiation.
- Q3 2025 results reflect strong execution across commercial, clinical, and operational fronts.

**【Q&A Key Highlights】**
- **IPF and PH Synergy**: Analysts asked about the potential for increased IPF diagnoses and Tyvaso sales following TETON 2 data. COO Michael Benkowitz noted early physician interest but cautioned it's too early to measure impact.
- **Ralinepag Partnership Potential**: CEO highlighted ralinepag's best-in-class efficacy, long patent life, and formulation flexibility for combination therapies. She expressed openness to partnerships with large pharma companies.
- **Revenue Guidance Clarity**: CEO clarified the $4 billion run rate target includes both PH and IPF growth, with Q3 2025 results underscoring confidence in achieving this by 2027.
- **Commercial Dynamics**: COO confirmed Tyvaso DPI maintains market share in both PAH and PH-ILD, with patient shipments and prescriber breadth metrics remaining strong post-YUTREPIA launch.
- **Regulatory Updates**: EVP of Product Development Leigh Peterson confirmed TETON-PPF trial enrollment is ~50% complete and the company is engaging with FDA to expedite IPF regulatory review.


UTHR

UTHR fundamentals

You can ask Aime